Copyright
©The Author(s) 2021.
World J Clin Oncol. May 24, 2021; 12(5): 342-354
Published online May 24, 2021. doi: 10.5306/wjco.v12.i5.342
Published online May 24, 2021. doi: 10.5306/wjco.v12.i5.342
Figure 3 Cell death is enhanced by thymoquinone alone and by the combination thymoquinone and royal jelly.
A: Representative density plots showing MDA-MB-231 cell distribution as a function of side scatter area and forward scatter area in the control and post-treatment with 15 µmol/L thymoquinone (TQ) and 0.1 µg/mL royal jelly alone and in combination for 24 h; B: Propidium iodide staining with flow cytometry showing the increase in Pre G1 upon treatment with TQ alone and the combination of TQ and royal jelly. Data shown are an average of three independent experiments expressed as mean ± standard error of the mean and analyzed by a two-way analysis of variance test followed by multiple comparisons test. Asterisks represent statistically significant results compared to the control, (aP < 0.05, bP < 0.01, cP < 0.001). RJ: Royal jelly; TQ: Thymoquinone.
- Citation: Moubarak MM, Chanouha N, Abou Ibrahim N, Khalife H, Gali-Muhtasib H. Thymoquinone anticancer activity is enhanced when combined with royal jelly in human breast cancer. World J Clin Oncol 2021; 12(5): 342-354
- URL: https://www.wjgnet.com/2218-4333/full/v12/i5/342.htm
- DOI: https://dx.doi.org/10.5306/wjco.v12.i5.342